Takeda Development Center Americas Reports Findings in Disease Progression (Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis): Disease Attributes – Disease Progression

2023 NOV 28 (NewsRx) -- By a News Reporter-Staff News Editor at Daily Asia Business -- New research on Disease Attributes - Disease Progression is the subject of a report. According to news reporting originating from Cambridge, Massachusetts, by NewsRx correspondents, research stated, “Alpha-1 antitrypsin deficiency is a rare genetic disease and a leading cause of inherited alterations in plasma protein metabolism (APPM). To understand the prevalence, burden and progression of liver disease in patients with APPM including alpha-1 antitrypsin deficiency.”

Our news editors obtained a quote from the research from Takeda Development Center Americas, “We conducted a retrospective analysis of anonymized patient-level claims data from a German health insurance provider (AOK PLUS). The APPM cohort comprised patients with APPM (identified using the German Modification of the International Classification of Diseases-10 Revision [ICD-10-GM] code E88.0 between 01/01/2010-30/09/2020) and incident liver disease (ICD-10-GM codes K74, K70.2-3 and K71.7 between 01/01/2012-30/09/2020). The control cohort comprised patients without APPM but with incident liver disease. Outcomes were incidence/prevalence of liver disease in patients with APPM, demographics/baseline characteristics, diagnostic procedures, progression-free survival (PFS), disease progression and mortality. Overall, 2680 and 26299 patients were included in the APPM (fibrosis, 96; cirrhosis, 2584) and control (fibrosis, 1444; cirrhosis, 24855) cohorts, respectively. Per 100000 individuals, annual incidence and prevalence of APPM and liver disease was 10-15 and 36-51, respectively. In the APPM cohort, median survival was 4.7 years [95% confidence interval (CI): 3.5-7.0] and 2.5 years (95%CI: 2.3-2.8) in patients with fibrosis and cirrhosis, respectively. A higher proportion of patients in the APPM cohort experienced disease progression (92.0%) compared with the control cohort (67.2%). Median PFS was shorter in the APPM cohort (0.9 years, 95%CI: 0.7-1.1) compared with the control cohort (3.7 years, 95%CI: 3.6-3.8; < 0.001). Patients with cirrhosis in the control cohort had longer event-free survival for ascites, hepatic encephalopathy, hepatic failure and esophageal/gastric varices than patients with cirrhosis in the APPM cohort (< 0.001). Patients with fibrosis in the control cohort had longer event-free survival for ascites, cirrhosis, hepatic failure and esophageal/gastric varices than patients with fibrosis in the APPM cohort (< 0.001). In the APPM cohort, the most common diagnostic procedures within 12 mo after the first diagnosis of liver disease were imaging procedures (66.3%) and laboratory tests (51.0%).”

According to the news editors, the research concluded: “Among patients with liver disease, those with APPM experience substantial burden and earlier liver disease progression than patients without APPM.”

This research has been peer-reviewed.

For more information on this research see: Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis. World Journal of Hepatology, 2023;15(10):1127-1139.

The news editors report that additional information may be obtained by contacting May Hagiwara, R&D, Global Evidence and Outcomes, Takeda Pharmaceutical Company Inc., Cambridge, MA 02139, United States. Additional authors for this research include Nils Picker, Severin Baumann, Ed G. Marins, Thomas Wilke, Kaili Ren, Ulf Maywald, Chitra Karki and Pavel Strnad.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.4254/wjh.v15.i10.1127. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)